4BIO Capital: Investment Portfolio & Startup News

4BIO Capital

To add a bio or update investment portfolio, please click update information.

Investment Portfolio

Cytospire Therapeutics secures £61m Series A led by 4BIO Capital for cancer therapies that activate the body’s immune cells

5 May 2026

Cytospire Therapeutics secures £61m Series A led by 4BIO Capital for cancer therapies that activate the body’s immune cells

Cytospire Therapeutics develops multispecific immune cell engager antibodies designed to enhance and direct the activity of the body’s immune system. Its platform targets gamma delta T cells to generate anti tumour immune responses for patients with cancer and other diseases.

4BIO Capital

- Life Sciences
1(12 months)
4biocapital.com
Update Information

More venture news

DYAD
29 Sept 2026
DYAD secures a £7.5m Series A led by Sangha Capital for its system that converts clinical documents into structured data for GP patient records
Series AHealth
Sprive
21 Sept 2026
Sprive unlocks an £8m Series A from VCs to help homeowners pay down their mortgages
Series AFintech
Magentic
17 Sept 2026
Magentic closes £13m Series A led by Felicis to put AI workers inside the procurement teams of global manufacturers
Series ASupply Chain

4BIO Capital: Investment Portfolio & Startup News

Investment Portfolio

Cytospire Therapeutics secures £61m Series A led by 4BIO Capital for cancer therapies that activate the body’s immune cells

More venture news

DYAD secures a £7.5m Series A led by Sangha Capital for its system that converts clinical documents into structured data for GP patient records

Sprive unlocks an £8m Series A from VCs to help homeowners pay down their mortgages

Magentic closes £13m Series A led by Felicis to put AI workers inside the procurement teams of global manufacturers